In what the agency called “a historic first,” FDA Commissioner Martin Makary announced an aggressive timeline to scale use of artificial intelligence (AI) internally across all FDA centers by June 30, 2025, following the completion of a new generative AI pilot for scientific reviewers.
The generative AI tools allow FDA scientists and